Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Pharma Sale Remains Long-Term Option; CFO Wenning To Become CEO

Executive Summary

Bayer AG is leaving open the possibility of a sale of its pharmaceutical division over the long-term, while emphasizing that it remains a "core" business for now.
Advertisement

Related Content

Bayer Finds Partial Pharma Partner In Aventis Blood Products Joint Venture
Bayer Finds Partial Pharma Partner In Aventis Blood Products Joint Venture
Bayer Seeking Smaller Pharma Partner; Will Retain Majority Share In Deal
Bayer Seeking Smaller Pharma Partner; Will Retain Majority Share In Deal
Bayer Changes Pharma Leadership On Eve Of U.S. Stock Listing
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Bayer Baycol Kansas City Facility Construction Halted Following Withdrawal
Advertisement
UsernamePublicRestriction

Register

PS038490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel